Position of the Transparency Council – Disulone (dapsoneum)
At its meeting on 23 September 2024, the Transparency Council adopted position No. 96/2024 On the appropriateness of issuing approvals for reimbursement of the drug Disulone (dapsoneum) in multiple indications
Publication of the position >>